Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Laboratory Corporation of America Holdings / Equity Bottom-Up

Laboratory Corporation of America Holdings

<ul><li>Laboratory Corporation of America Holdings (LabCorp) presented a mixed but generally positive financial report in their latest call, providing signals for investors to weigh both an optimistic outlook and some ongoing challenges.</li><li>LabCorp's performance in 2024 was highlighted by a 10% increase in revenue compared to the previous year, totaling $3.3 billion for the fourth quarter alone.</li><li>Their Diagnostics and Biopharma Laboratory Services segments each demonstrated a commendable 10% growth.</li></ul>

Laboratory Corporation of America Holdings (LabCorp) presented a mixed but generally positive financial report in their latest call, providing signals for investors to weigh both an optimistic outlook and some ongoing challenges.LabCorp's performance in 2024 was highlighted by a 10% increase in revenue compared to the previous year, totaling $3.3 billion for the fourth quarter alone.Their Diagnostics and Biopharma Laboratory Services segments each demonstrated a commendable 10% growth.

LH US - Labcorp Holdings: Is Its Stronghold in Diagnostics Under Threat?

<ul><li>Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although not without its challenges.</li><li>The company reported a revenue increase of 7% year-over-year to $3.3 billion, with Diagnostics Laboratories exhibiting a 9% growth while Biopharma Laboratory Services rose by approximately 3%.</li><li>Despite these growth figures, the company faced margin pressures, partially due to the integration of Invitae, resulting in a 40-basis point decrease in enterprise margins.</li></ul>

Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although not without its challenges.The company reported a revenue increase of 7% year-over-year to $3.3 billion, with Diagnostics Laboratories exhibiting a 9% growth while Biopharma Laboratory Services rose by approximately 3%.Despite these growth figures, the company faced margin pressures, partially due to the integration of Invitae, resulting in a 40-basis point decrease in enterprise margins.

Laboratory Corporation of America Holdings (LabCorp):  Advancement in Oncology Diagnostics & Other Major Highlights Of Q3 That Could Have A Long Term Impact! - Financial Forecasts

<ul><li>Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business operations.</li><li>The company reported impressive figures with revenues totaling $3.2 billion, reflecting a 6% increase compared to the same period in 2023.</li><li>Adjusted earnings per share (EPS) also saw an appreciable rise, reaching $3.94, signifying a 15% increase.</li></ul>

Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business operations.The company reported impressive figures with revenues totaling $3.2 billion, reflecting a 6% increase compared to the same period in 2023.Adjusted earnings per share (EPS) also saw an appreciable rise, reaching $3.94, signifying a 15% increase.

Laboratory Corporation of America Holdings (LabCorp): Expansion into Hospital & Regional Laboratory Markets & Focus on High-Growth Specialty Testing Markets! - Major Drivers

<ul><li>Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.</li><li>The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.</li><li>Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%.</li></ul>

Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%.

Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious.</li>
<li>A historic selloff has ensued and significant damage has been done as market dynamics have worsened.</li>
<li>Until we see some base-building process develop alongside improving market dynamics, we remain cautious and we continue to favor defensives as long as the SPX is below its 200-day MA.</li>
</ul>


Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious.
A historic selloff has ensued and significant damage has been done as market dynamics have worsened.
Until we see some base-building process develop alongside improving market dynamics, we remain cautious and we continue to favor defensives as long as the SPX is below its 200-day MA.


S&P 500 and Nasdaq 100 Testing Prior 2022 Highs; Still Bearish and Cautious

United States

Laboratory Corporation of America Holdings is a clinical laboratory company. The Company develops specialty testing operations, such as oncology testing, HIV genotyping, and phenotyping, diagnostic genetics, and clinical trials. Laboratory serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laboratory of America Hol (LH UN)

LH US - Labcorp Holdings: Is Its Stronghold in Diagnostics Under Threat?

Laboratory Corporation of America Holdings (LabCorp) presented a mixed but generally positive financial report in their latest call, providing...

Baptista Research

Laboratory Corporation of America Holdings (LabCorp): Advancement in Oncology Diagnostics & Other Major Highlights Of Q3 That Could Have A Long Term Impact! - Financial Forecasts

Labcorp Holdings has posted its financial results for the third quarter of 2024, reflecting robust growth and operational advancements, although...

Baptista Research

Laboratory Corporation of America Holdings (LabCorp): Expansion into Hospital & Regional Laboratory Markets & Focus on High-Growth Specialty Testing Markets! - Major Drivers

Labcorp Holdings Inc. delivered a robust performance in the second quarter of 2024, showcasing a continued upward trajectory in its business...

Baptista Research

Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers

Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for...

Baptista Research

S&P 500 and Nasdaq 100 Testing Prior 2022 Highs; Still Bearish and Cautious

$SPX and Nasdaq 100 $QQQ Testing Prior 2022 Highs; Upgrading Health Care $XLV; Downgrading Transportation $IYT; Still Bearish and Cautious; Sell...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)